Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 [Update on kinase inhibitors].

× No keyword cloud information.

14 in total

1. Strategies for the management of rheumatoid arthritis.

Authors: W S Wilkie; Philip Schwieterman
Journal: Orthopedics Date: 2012-02 Impact factor: 1.390

2. Associations between PXK and TYK2 polymorphisms and systemic lupus erythematosus: a meta-analysis.

Authors: Young Ho Lee; Sung Jae Choi; Jong Dae Ji; Gwan Gyu Song
Journal: Inflamm Res Date: 2012-05-17 Impact factor: 4.575

3. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.

Authors: Ronald F van Vollenhoven; Roy Fleischmann; Stanley Cohen; Eun Bong Lee; Juan A García Meijide; Sylke Wagner; Sarka Forejtova; Samuel H Zwillich; David Gruben; Tamas Koncz; Gene V Wallenstein; Sriram Krishnaswami; John D Bradley; Bethanie Wilkinson
Journal: N Engl J Med Date: 2012-08-09 Impact factor: 91.245

Review 4. Back to the future: oral targeted therapy for RA and other autoimmune diseases.

Authors: John J O'Shea; Arian Laurence; Iain B McInnes
Journal: Nat Rev Rheumatol Date: 2013-02-19 Impact factor: 20.543

5. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Authors: Claire Harrison; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Heinz Gisslinger; Roger Waltzman; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard Levy; Laurent Knoops; Francisco Cervantes; Alessandro M Vannucchi; Tiziano Barbui; Giovanni Barosi
Journal: N Engl J Med Date: 2012-03-01 Impact factor: 91.245

Review 6. The JAK-STAT pathway: impact on human disease and therapeutic intervention.

Authors: John J O'Shea; Daniella M Schwartz; Alejandro V Villarino; Massimo Gadina; Iain B McInnes; Arian Laurence
Journal: Annu Rev Med Date: 2015 Impact factor: 13.739

Review 7. Tofacitinib: a review of its use in adult patients with rheumatoid arthritis.

Authors: Lesley J Scott
Journal: Drugs Date: 2013-06 Impact factor: 9.546

8. Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy.

Authors: R E Alten; C Zerbini; S Jeka; F Irazoque; F Khatib; P Emery; A Bertasso; M Rabbia; J P Caulfield
Journal: Ann Rheum Dis Date: 2009-04-08 Impact factor: 19.103

Review 9. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases.

Authors: Daniella M Schwartz; Michael Bonelli; Massimo Gadina; John J O'Shea
Journal: Nat Rev Rheumatol Date: 2015-12-03 Impact factor: 20.543

10. Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies.

Authors: Jürgen Wollenhaupt; Joel Silverfield; Eun Bong Lee; Jeffrey R Curtis; Susan P Wood; Koshika Soma; Chudy I Nduaka; Birgitta Benda; David Gruben; Hiroyuki Nakamura; Yoshihiro Komuro; Samuel H Zwillich; Lisy Wang; Richard J Riese
Journal: J Rheumatol Date: 2014-04-01 Impact factor: 4.666